Robert B. Ford - 21 Feb 2024 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Role
CHAIRMAN AND CEO, Director
Signature
/s/ Robert B. Ford by Jessica H. Paik, Attorney-in-Fact
Issuer symbol
ABT
Transactions as of
21 Feb 2024
Net transactions value
$0
Form type
4
Filing time
23 Feb 2024, 17:27:37 UTC
Previous filing
02 Mar 2023
Next filing
04 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABT Common shares without par value Award $0 +70,332 +39% $0.000000 251,669 21 Feb 2024 Direct F1
holding ABT Common shares without par value 197,403 21 Feb 2024 Ford Family Trust F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABT Option (right to buy) Award $0 +264,293 $0.000000 264,293 21 Feb 2024 Common Shares 264,293 $116.98 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.
F2 Held in the Ford Family Trust DTD June 2, 2014. The reporting person is co-trustee of the trust.
F3 Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 88,097 on February 21, 2025, 88,098 on February 21, 2026, and 88,098 on February 21, 2027.